Revive Therapeutics Ltd (RVVTF)

$0.02 +0.00 (4.00%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 328,939
Avg Vol 161,596
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 32%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which i...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 888-901-0036
Fax: 905-248-3355
Address:
The Canadian Venture Building, 82 Richmond Street East, Toronto, Canada
BobWarner99
BobWarner99 Aug. 19 at 7:29 PM
$RVVTF https://www.morningstar.com/news/accesswire/1209358msn/revive-therapeutics-announces-proposed-shares-for-debt-settlement
0 · Reply
Dirtymartini66
Dirtymartini66 Aug. 19 at 5:50 PM
$RVVTF April, 2025 Buci Cancer PR (would really love to hear an update - NO DRDC gag order excuse for the silence on this one) : https://revivethera.com/2025/04/revive-therapeutics-to-investigate-bucillamines-potential-in-cancer-treatment/
1 · Reply
Dirtymartini66
Dirtymartini66 Aug. 19 at 5:33 PM
$RVVTF Bucillamine is being explored in early-stage academic and corporate discussions as a potential thiol donor to help neutralize reactive oxygen species and replenish glutathione in the tumor microenvironment (TME). However, there are no active, major commercial preclinical or clinical oncology trial programs dedicated to it; research efforts Broader experimental studies evaluating oral Bucillamine alongside other repositioned compounds on ultraviolet-induced skin tumor development in mice showed no significant delay in tumor onset or reduction in tumor numbers compared to controls.Clinical Focus: While Bucillamine has an established clinical safety profile in Asia for rheumatoid arthritis and has undergone late-stage evaluation for other indications like COVID-19, its active development pipeline centers on biodefense collaborations rather than cancer.
2 · Reply
BobWarner99
BobWarner99 Aug. 19 at 4:31 PM
$RVVTF MF, blink twice if you're trying to give the Market a clue about possible upcoming revenue deals that might possibly be on the horizon?? We know you're being muzzled for your own good but at least blink twice to let us know. 🙂
1 · Reply
Tartufo
Tartufo Aug. 19 at 3:37 PM
$RVVTF this company needs exposure
0 · Reply
Dirtymartini66
Dirtymartini66 Aug. 19 at 3:12 PM
$RVVTF DRDC Study finds that BUCI WORKS! 30+ YEARS OF USE IN HUMANS - MAJOR RE-RISKING ADVANTAGE MOST NEW DRUGS DON'T HAVE - Especially, important for a nerve agent drug that can't be tested in humans
1 · Reply
Dirtymartini66
Dirtymartini66 Aug. 19 at 3:06 PM
$RVVTF I think this is potentially huge: sounds like MF is going to shop the favorable DRDC results (and 30+ years of safety in humans as the cherry on top): " Our plan is straightforward: confirm what bucillamine may be able to do, pursue government-supported opportunities in Canada, the United States and allied markets"
0 · Reply
BobWarner99
BobWarner99 Aug. 19 at 2:03 PM
$RVVTF Getting heavier volume much earlier in the trading session. Could we possibly see a close above .0242 today?
0 · Reply
BobWarner99
BobWarner99 Aug. 19 at 1:54 PM
$RVVTF Was a muzzled MF allowed to drop some major hints??? It kinda sounds like a Ceo on a very short leash was allowed to drop some major easter eggs about possible upcoming revenue generating deals??? We'll see if this was the case or is it just a Ceo buying time? 🤔 https://www.stocktitan.net/news/RVVTF/revive-therapeutics-outlines-strategy-to-build-a-biodefence-and-gccka8oojs66.html
0 · Reply
Tartufo
Tartufo Aug. 19 at 1:53 PM
$RVVTF I am surprised with all this good news no one is buying
3 · Reply
Latest News on RVVTF
No data available.
BobWarner99
BobWarner99 Aug. 19 at 7:29 PM
$RVVTF https://www.morningstar.com/news/accesswire/1209358msn/revive-therapeutics-announces-proposed-shares-for-debt-settlement
0 · Reply
Dirtymartini66
Dirtymartini66 Aug. 19 at 5:50 PM
$RVVTF April, 2025 Buci Cancer PR (would really love to hear an update - NO DRDC gag order excuse for the silence on this one) : https://revivethera.com/2025/04/revive-therapeutics-to-investigate-bucillamines-potential-in-cancer-treatment/
1 · Reply
Dirtymartini66
Dirtymartini66 Aug. 19 at 5:33 PM
$RVVTF Bucillamine is being explored in early-stage academic and corporate discussions as a potential thiol donor to help neutralize reactive oxygen species and replenish glutathione in the tumor microenvironment (TME). However, there are no active, major commercial preclinical or clinical oncology trial programs dedicated to it; research efforts Broader experimental studies evaluating oral Bucillamine alongside other repositioned compounds on ultraviolet-induced skin tumor development in mice showed no significant delay in tumor onset or reduction in tumor numbers compared to controls.Clinical Focus: While Bucillamine has an established clinical safety profile in Asia for rheumatoid arthritis and has undergone late-stage evaluation for other indications like COVID-19, its active development pipeline centers on biodefense collaborations rather than cancer.
2 · Reply
BobWarner99
BobWarner99 Aug. 19 at 4:31 PM
$RVVTF MF, blink twice if you're trying to give the Market a clue about possible upcoming revenue deals that might possibly be on the horizon?? We know you're being muzzled for your own good but at least blink twice to let us know. 🙂
1 · Reply
Tartufo
Tartufo Aug. 19 at 3:37 PM
$RVVTF this company needs exposure
0 · Reply
Dirtymartini66
Dirtymartini66 Aug. 19 at 3:12 PM
$RVVTF DRDC Study finds that BUCI WORKS! 30+ YEARS OF USE IN HUMANS - MAJOR RE-RISKING ADVANTAGE MOST NEW DRUGS DON'T HAVE - Especially, important for a nerve agent drug that can't be tested in humans
1 · Reply
Dirtymartini66
Dirtymartini66 Aug. 19 at 3:06 PM
$RVVTF I think this is potentially huge: sounds like MF is going to shop the favorable DRDC results (and 30+ years of safety in humans as the cherry on top): " Our plan is straightforward: confirm what bucillamine may be able to do, pursue government-supported opportunities in Canada, the United States and allied markets"
0 · Reply
BobWarner99
BobWarner99 Aug. 19 at 2:03 PM
$RVVTF Getting heavier volume much earlier in the trading session. Could we possibly see a close above .0242 today?
0 · Reply
BobWarner99
BobWarner99 Aug. 19 at 1:54 PM
$RVVTF Was a muzzled MF allowed to drop some major hints??? It kinda sounds like a Ceo on a very short leash was allowed to drop some major easter eggs about possible upcoming revenue generating deals??? We'll see if this was the case or is it just a Ceo buying time? 🤔 https://www.stocktitan.net/news/RVVTF/revive-therapeutics-outlines-strategy-to-build-a-biodefence-and-gccka8oojs66.html
0 · Reply
Tartufo
Tartufo Aug. 19 at 1:53 PM
$RVVTF I am surprised with all this good news no one is buying
3 · Reply
Canadianbull1324
Canadianbull1324 Aug. 19 at 1:52 PM
$RVVTF PR is on fire!!
0 · Reply
sica1983
sica1983 Aug. 19 at 1:24 PM
$RVVTF a $10-$20 million government funding will send the stock 10x considering how tiny RVVTF is..this is defense medical program, very meaningful
0 · Reply
sica1983
sica1983 Aug. 19 at 1:10 PM
$RVVTF https://finance.yahoo.com/healthcare/articles/revive-therapeutics-outlines-strategy-build-124000057.html Strategically bullish news. Government funding should arrive soon imo🚀
2 · Reply
Tbickle
Tbickle Aug. 18 at 12:16 AM
$RVVTF MF will continue collect his fat salary & dilute shareholders. The cavalry is not coming. This is a long hold
1 · Reply
sica1983
sica1983 Aug. 17 at 9:21 PM
$RVVTF hmm…we closed red..so, highest daily volume in the past few weeks and suddenly people decided to sell their shares out of the blue after most awaited bullish news for the stock🤔 …fishy, market makers otc games imo
0 · Reply
Tbickle
Tbickle Aug. 17 at 8:07 PM
$RVVTF I'm adding at a penny
1 · Reply
BobWarner99
BobWarner99 Aug. 17 at 3:51 PM
$RVVTF Interesting trade volume before Noon....or not
0 · Reply
Dirtymartini66
Dirtymartini66 Aug. 17 at 2:15 PM
$RVVTF the DRDC news is great news - the news we were waiting for - however - we have to wait - but at least now - we have much better footing for our extended patience - and a chance to accumulate at extremely low levels - blessing in disguise, imo - best wishes all
0 · Reply
BobWarner99
BobWarner99 Aug. 17 at 12:00 AM
$RVVTF Could this be closer to .02 or .03 by the end of the week??? 🤔 https://www.stocktitan.net/news/RVVTF/revive-therapeutics-reports-grant-of-xcsdwg321s00.html
2 · Reply
JTM67
JTM67 Aug. 15 at 12:31 AM
$RVVTF Anybody else see the late Friday afteroon RVVTF announcement = Grant of Options = $15.5m ? That's MFank style just like when he had the last shareholder meeting " in person only" - couldn't even dial into a call line to hear the meeting. Friday afternoon to bury the news - what a Classless Clown...
6 · Reply
Lessworkmorefunds
Lessworkmorefunds Aug. 14 at 3:10 PM
$RVVTF this news release feels unusually restrained given the significance of the DRDC results. Remember, the March patent news triggered an ~88% move, yet this potentially much more important DRDC efficacy update has barely moved the stock. DRDC also controls what Revive can publicly disclose, so there may be considerably more context around the program that simply cannot be discussed yet. And if the Canadian government is ultimately looking at procurement, seems there's an obvious incentive for negotiations to happen before the market fully reprices the company. IMO the best is yet to come and this smells purposefully coordinate…
3 · Reply
BobWarner99
BobWarner99 Aug. 13 at 8:00 PM
$RVVTF So is it possible that we hear some more news regarding the nerve-agent find before Q4 2026?? But on any additional studies regarding potential effects on brain injury, 'oxidative stress (Molecular Hydrogen - 2025 DiagnaMed Holdings Corp acquisition ?) , response to standard treatment and respiratory function which starts in Q4 2026. So is MF now allowed to pursue partnership, revenue opportunities for the Nerve Agent research study while we wait for the additional studies scheduled for Q4 2026?
1 · Reply